ReviewFrontiers in cellular and infection microbiology2024
The tigecycline resistance mechanisms in Gram-negative bacilli.
Review in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Antimicrobial Resistance and Molecular Characteristics in Tigecycline-ResistantMicroorganisms · 2026Article
- Natural Products Beyond Inhibition: A Mechanistic Framework Spanning Pockets, Interfaces, and Kinetic Barriers.Molecules (Basel, Switzerland) · 2026Review
- Resistance associated genomic variations for moderate level tigecycline resistance evolution in Acinetobacter baumannii.World journal of microbiology & biotechnology · 2026Article
- Transcriptomic analysis of tigecycline-induced colistin collateral sensitivity in carbapenem-resistantmSphere · 2026Article
- Effect of sub-inhibitory tigecycline (½-MIC) on AcrAB-TolC andFrontiers in cellular and infection microbiology · 2026Article
- Distribution and antibiotic resistance analysis of clinically isolated bacteria at a national regional cardiovascular medical center, 2018-2024.BMC infectious diseases · 2025Article
- Transcriptomic Analysis of the Impact of theAnimals : an open access journal from MDPI · 2025Article
- Threat and Control ofFoods (Basel, Switzerland) · 2025Review
- In vitro activity of Eravacycline against carbapenem-resistant gram-negative bacilli and associated risk factors for non-susceptible infections from a tertiary hospital in fujian, China from 2021 to 2024.BMC microbiology · 2025Article
- Doxycycline: An essential tool for Alzheimer's disease.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Acquisition and Transmission ofInfection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tigecycline, hailed as a pivotal agent in combating multidrug-resistant bacterial infections, confronts obstacles posed by the emergence of resistance mechanisms in Gram-negative bacilli. This study explores the complex mechanisms of tigecycline resistance in Gram-negative bacilli, with a particular focus on the role of efflux pumps and drug modification in resistance. By summarizing these mechanisms, our objective is to provide a comprehensive understanding of tigecycline resistance in Gram-negative bacilli, thereby illuminating the evolving landscape of antimicrobial resistance. This review contributes to the elucidation of current existing tigecycline resistance mechanisms and provides insights into the development of effective strategies to manage the control of antimicrobial resistance in the clinical setting, as well as potential new targets for the treatment of tigecycline-resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.